Nuvalent - About the company
Nuvalent is an acquired company based in Cambridge (United States), founded in 2017. It operates as a Developer of therapeutic solutions for the treatment of cancer. Nuvalent has raised $185M in funding from Deerfield and Bain Capital Life Sciences, with last known valuation of $*****. The company has 3306 active competitors, including 1127 funded and 786 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio.
Company Details
Developer of therapeutic solutions for the treatment of cancer. The company is involved in the development of a novel drug candidate NUV-520 that is a ROS1-selective inhibitor that provides solutions for patients with NSCLC tumors. It also provides treatment solutions for patients with CNS metastasis. The drug candidate NUV-655 provides solutions for the treatment of lung cancer, breast cancer, & others.
- Website
- nuvalent.com
- Social
- Registered Address
- One Broadway 14th Floor Cambridge, Massachusetts 02142
Key Metrics
Founded Year
2017
Location
Cambridge, United States
Stage
Acquired
Total Funding
$185M in 2 rounds
Latest Funding Round
Last Known Valuation
$***** as on Jul 26, 2021
Ranked
155th among 3306 active competitors
Employee Count
310 as on Jul 31, 2026
Similar Companies
Exit Details
Acquired by GSK (Jun 09, 2026)
Legal entities associated with Nuvalent
Nuvalent is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Nuvalent, Inc. CIN: 6203574 , United States, Active | Jan 24, 2017 | - | 92 (As on Dec 31, 2023) | - |
Nuvalent's acquisition details
Click here to take a look at Nuvalent's acquisition in detail
Sign up to download Nuvalent's company profile
Nuvalent's funding and investors
Nuvalent has raised a total funding of $185M over 2 rounds. Its first funding round was on Jan 27, 2021. Its latest funding round was a Series B round on May 11, 2021 for $*****. 12 investors participated in its latest round. Nuvalent has 12 institutional investors.
Here is the list of recent funding rounds of Nuvalent:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
May 11, 2021 | 1568816 | Series B | 9750693 | 1627936 | 1274902 | 2614781 |
Jan 27, 2021 | 2466889 | Series A | 9644658 | 5718883 | 6124683 |
Access funding benchmarks and valuations. Sign up today!View details of Nuvalent's funding rounds and investors
Nuvalent's founders and board of directors
Founder? Claim ProfileNuvalent's employee count trend
Nuvalent has 310 employees as of Jul 26. Here is Nuvalent's employee count trend over the years:
Uncover Nuvalent's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Nuvalent's Competitors and alternates
Top competitors of Nuvalent include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Here is the list of Top 10 competitors of Nuvalent, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 75/100 | |
3rd | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 72/100 | |
5th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
6th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
7th | Karyopharm 2008, Newton (United States), Public | Biopharmaceutical company focused on developing and commercializing innovative cancer therapies | $98.4M | 71/100 | |
8th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 71/100 | |
9th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
10th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 71/100 | ||
155th |  Nuvalent 2017, Cambridge (United States), Acquired | Developer of therapeutic solutions for the treatment of cancer | $185M | 61/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Nuvalent's competitors? Click here to see the top ones
Nuvalent's Investments and acquisitions
Nuvalent has made no investments or acquisitions yet.
Reports related to Nuvalent
Here is the latest report on Nuvalent's geography:
News related to Nuvalent
Filter this listMedia has covered Nuvalent for a total of 41 events in the last 1 year, 18 of them have been about company updates and 1 about partnerships.
•
•
•
•
Shareholder Alert: M&A Law Firm Investigates Mergers Involving TMHC, NUVL, AXTA, and PFLCPR Newswire•Jun 25, 2026•Nuvalent, Taylor Morrison, GSK
•
•
GSK to Acquire Nuvalent for $1.6 Billion, Boosting Oncology PipelineShareprices•Jun 09, 2026•Nuvalent, GSK, Herbert Smith Freehills Kramer
•
•
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Nuvalent
Explore our recently published companies
